Skip to main content
SpringerLink
Log in

Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics of omeprazole and its metabolites were studied in 8 healthy elderly volunteers using [14C]omeprazole. In another 6 healthy elderly volunteers, the pharmacokinetics of omeprazole were studied using unlabelled drug. Each volunteer received single doses of omeprazole intravenously (20mg) and orally (40mg) as solutions in a randomised crossover design. The plasma concentrations and urinary excretion of omeprazole and metabolites were followed for 24 and 96h, respectively.

The results indicate that the average metabolic capacity of omeprazole is decreased in the elderly compared with that found in earlier studies of healthy young individuals. This was reflected in an increase in bioavailability from 56 to 76%, a reduction in mean systemic clearance by approximately 50% (0.25 L/min) and a prolongation of the mean elimination half-life from 0.7 to 1.0h compared with the young.

Despite these findings, the considerable overlap in these parameters between young and old volunteers, together with data from previous pharmacodynamic studies and the wide therapeutic range of omeprazole, indicate that dosage reductions are not needed in the elderly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andersson T, Cederberg C, Regårdh CG, Skånberg I. Pharmacokinetics of various single intravenous and oral doses of omeprazole. European Journal of Clinical Pharmacology 39: 195–197, 1990a

    Article  PubMed  CAS  Google Scholar 

  • Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Therapeutic Drug Monitoring 12: 415–416, 1990b

    Article  PubMed  CAS  Google Scholar 

  • Andersson T, Olsson R, Regårdh CG, Skånberg I. Pharmacokinetics of [14C]omeprazole in patients with liver cirrhosis. Clinical Pharmacokinetics, in press, 1993

    Google Scholar 

  • Bardhan KD, Bianchi Porro G, Bose K, Daly M, Hinchliffe RFC, et al. A comparison of two different doses of omeprazole versus ranitidine in treatment of duodenal ulcers. Journal of Clinical Gastroenterology 8: 408–413, 1986

    Article  PubMed  CAS  Google Scholar 

  • Brändström A, Lindberg P, Bergman NÅ, Alminger T, Ankner K, et al. Chemical reactions of omeprazole and omeprazole analogues. Acta Chemica Scandinavica 43: 536–611, 1989

    Article  Google Scholar 

  • Fellenius E, Berglindh T, Sachs G, Olbe L, Elander B, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+, K+)ATPase. Nature 290: 159–161, 1981

    Article  PubMed  CAS  Google Scholar 

  • Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. New England Journal of Medicine 306: 1081–1088, 1982

    Article  PubMed  CAS  Google Scholar 

  • Grundevik I, Jerndal G, Balmér K, Persson BA. Fully automated gradient elution liquid Chromatographic assay of omeprazole and 2 metabolites. Journal of Pharmacology and Biomedical Analysis 4: 389–398, 1986

    Article  CAS  Google Scholar 

  • Hetzel DJ, Dent J, Reed WD, Narielvala FM, Mackinnon M, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 95: 903–912, 1988

    PubMed  CAS  Google Scholar 

  • Klinkenberg-Knol EC, Jansen JMBJ, Festen HPM, Meuwissen SGM, Lamers CBHW. Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet 1: 349–351, 1987

    Article  PubMed  CAS  Google Scholar 

  • Lamy P. Modifying drug dosage in elderly patients. In Covington & Walker (Eds) Current Geriatric Therapy, pp. 35–72, Saunders Company, Philadelphia, 1984

    Google Scholar 

  • Larsson M, Jagenburg R, Landahl S. Renal function in an elderly population. A study of S-creatinine, 51Cr-EDTA clearance, endogenous creatinine clearance and maximal tubular water reabsorption. Scandinavian Journal of Clinical and Laboratory Investigation 46: 593–598, 1986

    Article  PubMed  CAS  Google Scholar 

  • Lind T, Andersson T, Skånberg I, Olbe L. Biliary excretion of intravenous [14C)omeprazole in humans. Clinical Pharmacology and Therapeutics 42: 504–508, 1987

    Article  PubMed  CAS  Google Scholar 

  • Lind T, Cederberg C, Axelson M, Olbe L. Long-term acid inhibitory effect of different daily doses of omeprazole 24 hours after dosing. Scandinavian Journal of Gastroenterology 21 (Suppl. 118): 137–138, 1986

    Article  Google Scholar 

  • Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole — a gastric proton pump inhibitor — on pentagastrin stimulated acid secretion in man. Gut 24: 270–276, 1983

    Article  PubMed  CAS  Google Scholar 

  • Lind T, Cederberg C, Olausson M, Olbe L. Omeprazole in elderly duodenal ulcer patients: relationship between reduction in gastric acid secretion and fasting plasma gastrin. European Journal of Clinical Pharmacology 40: 557–560, 1991

    PubMed  CAS  Google Scholar 

  • Loo JCK, Riegelman S. Assessments of pharmacokinetic constants from post infusion blood curve obtained after iv infusion. Journal of Pharmaceutical Sciences 59: 53–57, 1970

    Article  PubMed  CAS  Google Scholar 

  • Lorentzon P, Eklundh B, Brändström A, Wallmark B. The mechanism for inhibition of gastric (H++K+)-ATPase by omeprazole. Biochimica et Biophysica Acta 817: 25–32, 1985

    Article  PubMed  CAS  Google Scholar 

  • Naesdal J, Andersson T, Bodemar G, Larsson R, Regårdh CG, et al. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. Clinical Pharmacology and Therapeutics 40: 344–351, 1986

    Article  PubMed  CAS  Google Scholar 

  • Regårdh CG, Andersson T, Lagerström PO, Lundborg P, SkÅnberg I. The pharmacokinetics of omeprazole in humans — a study of single intravenous and oral doses. Therapeutic Drug Monitoring 12: 163–172, 1990

    Article  PubMed  Google Scholar 

  • Regårdh CG, Gabrielsson M, Hoffman KJ, Löfberg I, Skånberg I. Pharmacokinetics and metabolism of omeprazole in animals and man — an overview. Scandinavian Journal of Gastroenterology 20 (Suppl. 108): 79–94, 1985)

    Article  Google Scholar 

  • Sheiner LB, Beal SL. Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. Journal of Pharmacokinetics and Biopharmaceutics 13: 185–201, 1985

    PubMed  CAS  Google Scholar 

  • Schmucker DL, Woodhouse KW, Wang RK, Wynne H, James OF, et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clinical Pharmacology and Therapeutics 48: 365–374, 1990

    Article  PubMed  CAS  Google Scholar 

  • Vestal RE. Drug use in the elderly: a review of problems and special considerations. Drugs 16: 358–382, 1978

    Article  PubMed  CAS  Google Scholar 

  • Vestal RE. Aging and determinants of hepatic drug clearance. Hepatology 9: 331–334, 1989

    Article  PubMed  CAS  Google Scholar 

  • Walan A, Bader JP, Classen M, Lamers CBHW, Piper DW, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. New England Journal of Medicine 320: 69–75, 1989

    Article  PubMed  CAS  Google Scholar 

  • Wallmark B, Lorentzon P, Larsson H. The mechanism of action of omeprazole — a survey of its inhibitory actions in vitro. Scandinavian Journal of Gastroenterology 20 (Suppl. 108): 37–51, 1985

    Google Scholar 

  • Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 9: 297–301, 1989

    Article  PubMed  CAS  Google Scholar 

  • Wynne HA, Goudevenos J, Rawlins MD, James OFW, Adams PC, et al. Hepatic drug clearance: the effect of age using indocyanine green as a model compound. British Journal of Clinical Pharmacology 30: 634–637, 1990

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Geriatric and Longterm Care Medicine, Clinic IV, Vasa Hospital, Göteborg, Sweden

    Sten Landahl, Tommy Andersson, Mayethel Larsson, Bodil Lernfeldt, Per Lundborg, Carl-Gunnar Regårdh, Eva Sixt & Inger Skånberg

  2. Astra Hässle AB, Mölndal, Sweden

    Sten Landahl, Tommy Andersson, Mayethel Larsson, Bodil Lernfeldt, Per Lundborg, Carl-Gunnar Regårdh, Eva Sixt & Inger Skånberg

Authors
  1. Sten Landahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tommy Andersson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mayethel Larsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bodil Lernfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Per Lundborg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carl-Gunnar Regårdh
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eva Sixt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Inger Skånberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landahl, S., Andersson, T., Larsson, M. et al. Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers. Clin. Pharmacokinet. 23, 469–476 (1992). https://doi.org/10.2165/00003088-199223060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199223060-00006

Keywords

Search

Navigation